Transglycosylation of IgG
TransGLYCIT is a platform technology that enables efficient and site-specific human IgG glycan remodeling. With TransGLYCIT, antibodies with defined and homogenous glycoforms are generated using fast and robust enzymatic workflows.
TransGLYCIT Remodeling generates a homogenous pool of antibodies carrying the G0, G1, G2 or G2S2 glycan profile with the core fucosylation intact, and TransGLYCIT Remodeling Afucosylated generates a homogenous pool of antibodies carrying the G0, G1, G2, G2S2 or Man5 glycan profile with core afucosylation.
- Efficient and site-specific human IgG Fc N-glycan remodeling
- Prepares human IgG with homogenous glycoprofiles
- A rapid workflow – transglycosylation is completed within a few hours
at the Fc N-glycan sites
TransGLYCIT™ Remodeling
Glycan remodeling of human IgG with the G0, G1, G2 or G2S2 glycoformTransGLYCIT™ Remodeling Afucosylated
Glycan remodeling of human IgG with the G0, G1, G2, G2S2 or Man5 glycoform, with core afucosylationAbout TransGLYCIT™
- Deglycosylation
The Fc N-glycans are trimmed to the core GlcNAc using the IgG-specific GlycINATOR® Immobilized (EndoS2) enzyme that hydrolyses all Fc glycoforms, including high-mannose, hybrid, complex and bisecting glycans. For TransGLYCIT Remodeling, the degree of core fucosylation is the same as on the original IgG. It is possible to obtain afucosylated G0, G1, G2, G2S2 or Man5 glycoforms using TransGLYCIT Remodeling Afucosylated, where the FucosEXO™ 16 Immobilized enzyme hydrolyzes the α1,6-linked core fucose prior to the transglycosylation step. - Transglycosylation
The engineered glycosynthase TransINATOR™ catalyzes the transglycosylation reaction between the oxazoline-reactive G0, G1, G2, G2S2 or Man5 glycoform and the core GlcNAc.
The transglycosylation of IgG is followed by an affinity purification step.
The enzymes in TransGLYCIT are expressed in E. coli and modified with His-tags.
TransGLYCIT™ Citations
TransGLYCIT™ Remodeling
Glycan remodeling of human IgG with the G0, G1, G2 or G2S2 glycoform.
TransGLYCIT Remodeling is a platform technology for efficient transglycosylation of native human IgG in a few hours. The robust workflow transglycosylates the antibody Fc N-glycans using enzymatic remodeling, resulting in a homogenous pool of antibodies carrying a defined glycoform. The technology is available in kits to generate antibodies carrying the G0, G1, G2 or G2S2 glycan profiles.
TransGLYCIT Remodeling contains sufficient material to transglycosylate 1 mg human IgG. The glycan-remodeled sample will have the same degree of fucosylation as the original molecule. If you wish to remove core fucosylation, we recommend using TransGLYCIT Remodeling Afucosylated.
- Fast and efficient generation of human IgG with homogeneous glycoforms
- Facilitates functional analysis of specific glycan structures
- Reliable glycan remodeling achieved within a few hours
Available Products
For information on how to order, visit Place an Order or contact us directly at order@genovis.com.
TransGLYCIT Remodeling Citations
Unit Definition
TransGLYCIT transglycosylates ≥ 95% of 1 mg human IgG1 as measured by LC-MS.
Content and Storage
TransGLYCIT Remodeling contains:
- GlycINATOR Immobilized Microspin
- TransINATOR enzyme
- Oxazoline glycoform G0, G1, G2 or G2S2
- CaptureSelect™* Fc(ms) Microspin column for purification
TransGLYCIT Remodeling is shipped cold, and the content should be stored at different temperatures upon arrival.
Do not freeze the GlycINATOR Immobilized or the CaptureSelect™ columns!
Instructions
Safety Data Sheet
Certificate of Analysis
* Thermo Scientific™ CaptureSelect™ resin from Thermo Fisher Scientific Inc. and its subsidiaries. Thermo Fisher and CaptureSelect are trademarks of Thermo Fisher Scientific Inc. and its subsidiaries.
TransGLYCIT™ Remodeling Afucosylated
Glycan remodeling of human IgG with the G0, G1, G2, G2S2 or Man5 glycoform, with core afucosylation.
TransGLYCIT Remodeling Afucosylated is a platform technology for efficient transglycosylation of native human IgG in a few hours. The robust workflow transglycosylates the antibody Fc N-glycans using enzymatic remodeling, resulting in a homogenous pool of antibodies carrying a defined glycoform (G0, G1, G2, G2S2 or Man5) with core afucosylation.
TransGLYCIT Remodeling Afucosylated is provided in kits containing sufficient material to transglycosylate 1 mg human IgG.
- Fast and efficient generation of human IgG with fully afucosylated homogeneous glycoforms
- Complete removal of core fucose to investigate its impact in functional assays
- Reliable glycan remodeling achieved within a few hours
Available Products
For information on how to order, visit Place an Order or contact us directly at order@genovis.com.
Unit Definition
TransGLYCIT transglycosylates ≥ 95% of 1 mg human IgG1 as measured by LC-MS.
Content and Storage
TransGLYCIT Remodeling Afucosylated contains:
- GlycINATOR/FucosEXO 16 Immobilized Microspin
- TransINATOR enzyme
- Oxazoline glycoform G0, G1, G2, G2S2 or Man5
- CaptureSelect™* Fc(ms) Microspin column for purification
TransGLYCIT Remodeling Afucosylated is shipped cold, and the content should be stored at different temperatures upon arrival.
Do not freeze the GlycINATOR/FucosEXO 16 Immobilized or the CaptureSelect™ columns!
Instructions
Safety Data Sheet
Certificate of Analysis
* Thermo Scientific™ CaptureSelect™ resin from Thermo Fisher Scientific Inc. and its subsidiaries. Thermo Fisher and CaptureSelect are trademarks of Thermo Fisher Scientific Inc. and its subsidiaries.
FAQ and Support
Popular FAQ
Unfortunately no, the enzyme requires trimming of the Fc-glycan using GlycINATOR to enable access to the core fucose substrate.
No, TransGLYCIT is based on IgG specific enzymes and will only transglycosylate IgG.
GlycINATOR is an IgG specific endoglycosidase that hydrolyzes complex, hybrid and high mannonse type glycans on the conserved Fc site on IgG.
The TransGLYCIT platform is developed for transglycosylation of human IgG.
Yes, the transglycosylation reaction can be performed on all subclasses of human IgG. The reaction is somewhat slower on IgG2 and longer incubation times may be necessary to obtain over 95% transglycosylation.